Member Info for neilrich3

The figures are ahead of the consensus.

It was only Mid November when the Directors and consultant purchased their shares, I believe that everything is still on track.

It's a Bear Trap, in my opinion, they've deliberately held something back, expect some big announcements in the the weeks ahead.

I'd say that it was bang on the consensus.

In addition, the Company continues to support the DHSC and the NHS following the deployment of its rapid PCR testing system, for the contract with the DHSC, announced on 29 September 2020, and the Company is in active discussions with the DHSC to extend this phase of the contract.

£187 million Profit.

Perhaps still in the office because they are drafting such a colossal RNS for release at 0700 in the morning.

LORDINVESTOR thinks that a PE of approx 4 (based upon consensus) "Too high for me"

Instead suggests investing in a company that has come late to the party and has no orders. lol

I'd say that the trading update is as important as the figures for 2020, imagine an announcement re. the launch of new products.

Do we know the specific date for the trading update, or anytime before end of Jan?

Q&A? NCYT shall not be announcing the full year results until the late spring, why would they have an analyst Q&A next week?

There might be a trading update next week, with updated guidance and provisional revenue for 2020, but nothing more.

Don't get carried away, otherwise next weekend many shall be most disappointed.

Correct me if I'm wrong, however I think you shall find it was up 775% in the 4th quarter and not for the year.

https://www.telegraph.co.uk/politics/2021/01/17/exclusive-mass-testing-entire-regions-considered-ministers-signal/
Mass testing of entire regions is being considered by ministers to help get the country out of lockdown, it has emerged, as Dominic Raab said restrictions could start to be eased in March.

The Foreign Secretary said that by the "early spring, hopefully March" some restrictions would be lifted "gradually" so the country could "get back to normal”.

He warned it would not be a “big bang” end to lockdown but a return to tiers depending on the level of Covid admissions in hospitals, death rates and hitting targets on vaccinating the over 50s and vulnerable by early spring.

The Telegraph understands mass testing could be used to swiftly move the worst-infected areas down the tiers. One idea under consideration is to send out home testing kits, known as lateral flow tests, to every household in an entire region so the population could be tested within a week.

Don't wish to pay over the odds for Optigene, that's the danger...too late in the day.

Imagine...what if they were to announce a dividend, perhaps £35 million (50p a share). Not impossible, especially when you consider we have zero debt.

With a number of Novacyt patents, any idea as to what we might be receiving in royalties?

As a large NCYT investor I hope you're correct....simply asking the question for the purposes of a balanced view.

Why would Thermo Fisher takeover NCYT? What do we have that Thermo Fisher don't, we are small fry in comparison and surly Thermo Fisher need simply increase capacity organically! Not like we are a threat.

We shall never know whether that was a buy or a sell, impossible to tell, the system is nothing more than indicative.

Possibly due to the breaking news about travellers requiring a test before entering the UK, ports and airports.

We also have rapid testing for all hospital patients now, in stark contrast to the spring...
https://www.telegraph.co.uk/news/2021/01/02/like-work-covid-ward-second-wave-accelerates/

Thanks Jake, interesting to hear your take. Don't think we can be certain as to what the new 'norm' shall be, assuming GRG can get back to circa £80m annual profit, the current £1.7 billion market cap would still be greater than 20 times earnings, that's still a high valuation for any company.

VOD looks a far better prospect for 2021 valued at just 14 times earnings and a 6% yield and peg 0.5.

With regards to NCYT, it is trading at approximately 3 times earnings and possibly less than 2, the company has no debt and PEG 0.5. Appears to be a true growth stock and has established a niche position in a sector within a global market. Which is why I like to make the comparison with GRG at >40 earnings in a domestic market with much high street competition.

Thanks for the debate and Merry Christmas.